Neurocrine biosciences, inc. (NBIX)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash Flows from Operating Activities:
Net loss

37,012

21,111

-142,542

-141,090

-88,929

-60,542

-46,090

5,025

37,571

-7,968

-51,038

Reconciliation of net income (loss) to net cash provided by (used in) operating activities:
Share-based compensation expense

75,262

58,068

42,522

28,464

28,392

10,382

6,819

5,479

2,918

3,133

5,539

Depreciation

7,500

4,000

2,400

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

1,453

1,009

827

671

657

694

1,436

3,179

Amortization of debt discount

18,922

17,552

10,937

0

0

-

-

-

-

-

-

Amortization of debt issuance costs

1,389

1,326

848

0

0

-

-

-

-

-

-

Net (accretion of discounts) amortization of premiums on investments

1,965

-1,449

-1,756

-3,520

-6,032

-3,792

-2,843

-3,135

-2,341

-833

-

Change in fair value of equity security investments

-12,987

0

0

-

-

-

-

-

-

-

-

Deferred revenues

-

-

-

-

10,231

0

-2,919

-34,242

-37,027

62,490

-2,914

Deferred rent

-

-

-

-294

-16

14

142

305

434

680

796

Gain on sales of assets, net

-

-

-

3,431

3,334

3,222

3,170

3,074

3,195

3,161

3,626

Fair value adjustment for auction rate security rights

-

-

-

-

-

-

-

-

-

-

-815

Loss on sale of investments

-

-

-

-

-

-

-

-

-

-186

-1,086

Realized gain on sale of auction rate securities

-

-

-

-

-

-

-

-

-

1,320

124

Fair value adjustment of auction rate securities

-

-

-

-

-

-

-

-

-

-

1,047

Other-than-temporary impairment for auction rate securities

-

-

-

-

-

-

-

-

-

-

-1,431

Cease-use expense

-

-

-

-584

-85

0

0

1,092

82

2,799

5,984

Other

754

-409

-1,445

-

-

-

-

-

-

-

-

Change in operating assets and liabilities:
Accounts receivable

69,169

25,113

31,127

0

0

-

-

-

-

-

-

Inventory

6,424

3,524

1,024

0

0

-

-

-

-

-

-

Reimbursements for tenant improvements

-

-

-

0

-

-

-

-

-

-

-

Other current assets

-

-

-

-

489

-

-

-

-

-

-

Accounts payable and accrued liabilities

53,955

24,223

27,338

4,398

9,841

3,698

-949

-557

149

985

-4,076

Other current assets and liabilities, net

-21,879

-2,657

3,994

-1,383

-

-

-

-

-

-

-

Cease-use liability

-

-

-

-

-610

-418

-590

-263

-7,502

-4,537

-9,851

Accounts receivable under collaboration agreements and other assets

-

-

-

-

-

1,671

-13,528

12,878

-2,813

4,278

-2,449

Other liabilities

-

-

-

-

-39

0

108

27

24

-1,335

-1,698

Net cash provided by (used in) operating activities

152,054

101,364

-94,331

-106,181

-37,997

-47,140

-29,607

-35,294

-698

49,943

-53,095

Cash Flows from Investing Activities:
Purchases of marketable securities

797,169

545,962

583,408

298,776

449,052

257,544

145,328

166,313

139,099

89,787

16,800

Sales and maturities of marketable securities

669,691

327,825

339,088

415,826

255,123

154,133

151,281

132,520

134,276

34,839

27,615

Purchases of equity securities

68,855

0

0

-

-

-

-

-

-

-

-

Purchases of property and equipment

14,748

24,812

6,940

4,108

1,934

1,612

545

971

750

315

35

Deposits and restricted cash

-

-

-

-

-40

388

108

29

-1,796

-223

-84

Proceeds from sales of property and equipment

8

34

7

13

9

45

40

32

245

336

1,193

Net cash provided by investing activities

-211,073

-242,915

-251,253

112,955

-195,814

-105,366

5,340

-34,761

-3,532

-54,704

12,057

Cash Flows from Financing Activities:
Issuance of common stock

27,313

29,530

13,865

2,390

276,992

138,731

5,302

83,702

286

21,483

9,900

Proceeds from issuance of convertible senior notes, net

0

0

502,781

0

0

-

-

-

-

-

-

Net cash provided by financing activities

27,313

29,530

516,646

2,390

276,992

138,731

5,302

83,702

286

21,483

9,900

Change in cash and cash equivalents and restricted cash

-31,706

-112,021

171,062

9,164

43,181

-13,775

-18,965

13,647

-3,944

16,722

-31,138

Supplemental Disclosure:
Cash paid for interest

11,644

11,644

6,242

0

0

-

-

-

-

-

0

Cash paid for income taxes

507

0

0

-

0

0

0

0

0

0

0

Non-cash capital expenditures

953

2,318

0

0

-

-

-

-

-

-

-